Literature DB >> 15335304

Safety and side effect profile of fluoxetine.

Joachim F Wernicke1.   

Abstract

Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders. Its attributes have been described in numerous scientific papers, and it has been the subject of a considerable volume of lay press. Fluoxetine is generally safe and well-tolerated. Common adverse events reported with the recommended dose of 20 mg/day are referable to the gastrointestinal system and the nervous system. The approved dose range is up to 80 mg/day, and when higher doses are used, adverse events are more common. The long half-life of fluoxetine and its active metabolite essentially preclude a withdrawal phenomenon. It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions. However, most of these are not clinically important. The purpose of this review is to provide an overview of some of the most important information related to safety and side effects of this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15335304     DOI: 10.1517/14740338.3.5.495

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  12 in total

1.  Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF-TrkB Signaling.

Authors:  Kun Li; Si Shen; Yu-Tian Ji; Xu-Yun Li; Li-San Zhang; Xiao-Dong Wang
Journal:  Neurosci Bull       Date:  2017-10-31       Impact factor: 5.203

2.  Selective serotonin reuptake inhibitors facilitate ANO6 (TMEM16F) current activation and phosphatidylserine exposure.

Authors:  Hyun Jong Kim; Ikhyun Jun; Jae Seok Yoon; Jinsei Jung; Yung Kyu Kim; Woo Kyung Kim; Byung Joo Kim; Jaewoo Song; Sung Joon Kim; Joo Hyun Nam; Min Goo Lee
Journal:  Pflugers Arch       Date:  2015-01-30       Impact factor: 3.657

3.  Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation.

Authors:  Risha Ganguly; Ramesh Kumar; Abhay K Pandey
Journal:  World J Hepatol       Date:  2022-04-27

4.  Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis.

Authors:  M Sudhakara Rao; D Dwarakanatha Reddy; P S N Murthy
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-01-09

5.  The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.

Authors:  K A Rahn; Y-J Cao; C W Hendrix; A I Kaplin
Journal:  Transl Psychiatry       Date:  2015-05-05       Impact factor: 6.222

Review 6.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

7.  Can fluoxetine mitigate mental health decline in musculoskeletal trauma patients: a pilot single-center randomized clinical trial.

Authors:  Elizabeth Lossada-Soto; Marissa Pazik; Mary Beth Horodyski; Terrie Vasilopoulos; Ludmila Barbosa de Faria; Carol Mathews; Jennifer Hagen
Journal:  Pilot Feasibility Stud       Date:  2022-08-17

Review 8.  Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Authors:  Hansen Wang; Sandipan Pati; Lucas Pozzo-Miller; Laurie C Doering
Journal:  Front Cell Neurosci       Date:  2015-02-26       Impact factor: 5.505

9.  Protective Effects of Caffeic Acid Phenethyl Ester on Fluoxetine-Induced Hepatotoxicity: An Experimental Study.

Authors:  Ahmet Yılmaz; Bilal Elbey; Ümit Can Yazgan; Ahmet Dönder; Necmi Arslan; Serkan Arslan; Ulaş Alabalık; Hamza Aslanhan
Journal:  Biomed Res Int       Date:  2016-04-10       Impact factor: 3.411

Review 10.  Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms.

Authors:  Sabine Eschlböck; Gregor Wenning; Alessandra Fanciulli
Journal:  J Neural Transm (Vienna)       Date:  2017-10-22       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.